Epaned is an anti-heart failure and hypertension drug owned by Azurity. This drug, which contains the active ingredient enalapril maleate, was first authorized for market use on September 20, 2016. Epaned holds a total of 9 drug patents, none of which have expired as of now.
The expiration date of the last patent for Epaned is slated for March 25, 2036. This means that the potentials for a Epaned generic to be released is earliest after this date.
Epaned is used in the treatment of conditions such as heart failure and hypertension. Thanks to its active ingredient, enalapril maleate, it is also effective in treating left ventricular dysfunction. Epaned is available in the form of an oral solution.
Epaned carries a number of patents, all themed around Enalapril formulations. The earliest that a Epaned generic could potentially be launched is post March 25, 2036, following the expiration of the last patent. Below are the details of the patent: